瑞舒伐他汀联合非诺贝特治疗老年混合性高脂血症

Efficacy and Safety of Rosuvastatin Combined with Fenofibrate Treatment on Old Adults with Mixed Hyperlipidemia

目的探讨瑞舒伐他汀联合非诺贝特治疗老年混合性高脂血症的疗效及安全性。方法将80例老年混合性高脂血症患者随机分为2组,对照组39例,给予瑞舒伐他汀10 mg,每晚1次治疗,观察组41例,在对照组的基础上加用非诺贝特200 mg每日1次早上服用,8周为1个疗程,观察2组患者降脂的疗效及不良反应发生情况。结果观察组41例,显效18例,有效21例,无效2例,总有效率95.12%;对照组39例,显效14,有效18例,无效7例,总有效率82.05%,两组比较,差异有统计学意义(P<0.05)。两组治疗后与治疗前比较,TC、TG、LDL-C及HDL-C水平的变化均有显著改善,差异有统计学意义(P<0.05),观察组治疗后的TG、LDL-C的改善情况优于对照组,差异有统计学意义(P<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论瑞舒伐他汀联合非诺贝特治疗老年混合性高脂血症可提高疗效,安全可靠。

OBJECTIVE To investigate the efficacy and safety of rosuvastatin combined with fenofibrate treatment on old patients with mixed hyperlipidemia. METHODS 80 elderly patients with mixed hyperlipidemia were randomly divided into two groups. 39 cases in the control group received rosuvastatin 10 mg,once per night; 41 cases in the treatment group,received fenofibrateonce 200 mg daily in the morning as well as rosuvastatin. Eight weeks for one course of the treatment. The lipid-lowering effects and adverse reactions of two groups were evaluated. RESULTS The total effective rate was 95. 12% in the observation group and 82. 05% in the control group,with statistical significance between the two groups. After treatment,the TC,TG,LDL-C,and HDL-C levels in the two groups were significantly improved（ P〈0.05）,and the TG,LDL-C level of the observation group was changed more than the control group（ P〈0. 05）. There was no significant difference between two groups in the rate of adverse reactions. CONCLUSION Rosuvastatin combined with fenofibrate treatment on mixed hyperlipidemia of elders can improve the efficiency,and with a good safety profile.